Search
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalAs of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnThese are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.
PRX-P4-003
go.drugbank.com/drugs/DB33967ExperimentalPRX-P4-003 is under investigation in clinical trial NCT04638803 (A Phase 0, Open-Label, Crossover Microdose Pharmacokinetic Study of PRX-P4-003 in Healthy Volunteers).
Fludiazepam
go.drugbank.com/drugs/DB01567IllicitInvestigationalIt is a scheduled drug in the U.S., but is approved for use in Japan.
Bombesin
go.drugbank.com/drugs/DB11724Investigational-7548 in Patients With Prostate Cancer and Healthy Volunteers). … Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86
Trastuzumab botidotin
go.drugbank.com/drugs/DB17413ExperimentalA166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable
2X-121
go.drugbank.com/drugs/DB16063Investigational2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the
BGT-DTDS
go.drugbank.com/drugs/DB18664ExperimentalBGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human _SLC6A3_ gene.
AZD-8186
go.drugbank.com/drugs/DB15029InvestigationalAZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot